# BCLI catalysts: BRAINSTORM CELL THERAPEUTICS INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bcli/catalysts

> BRAINSTORM CELL THERAPEUTICS INC. (BCLI) has 2 upcoming catalysts. The next is the debamestrocel - msc-ntf (nurown) primary completion, November 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | BRAINSTORM CELL THERAPEUTICS INC. |
| Ticker | BCLI (OTC) |
| SEC CIK | 1137883 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/bcli |

## Cash runway

Cash $22K as of 2026-06-30; quarterly burn $895K; about 0.1 months of runway at that rate (XBRL company facts, accession 0001104659-26-097275).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 24, 2021 | [NurOwn (debamestrocel) topline data readout](https://sec-api.dev/pdufa/debamestrocel) | BCLI |  | completed, positive | "On March 24, 2021, we announced positive top-line data from our Phase 2 trial evaluating three repeated intrathecal administrations of NurOwn®, each given 2 months apart, as a treatment for PMS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1137883/000141057824002000/bcli-20240930x10q.htm)) |
| September 9, 2022 | [NurOwn (debamestrocel) NDA/BLA submission](https://sec-api.dev/pdufa/debamestrocel) | BCLI |  | completed | "On September 9, 2022, we filed a BLA to the FDA for NurOwn® for the treatment of ALS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1137883/000110465925112701/bcli-20250930x10q.htm)) |
| September 22, 2023 | [NurOwn (debamestrocel) NDA/BLA submission](https://sec-api.dev/pdufa/debamestrocel) | BCLI | mild to moderate ALS | completed | "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1137883/000110465926097275/bcli-20260630x10q.htm)) |
| November 14, 2024 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465924119041/tm2428354d1_ex99-1.htm)) |
| March 31, 2025 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925029608/tm2510890d2_ex99-1.htm)) |
| May 15, 2025 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "-- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_ex99-1.htm)) |
| August 14, 2025 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925078116/tm2523508d1_ex99-1.htm)) |
| November 10, 2025 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925112682/tm2531319d1_ex99-1.htm)) |
| 2026 | [NurOwn (debamestrocel) trial start](https://sec-api.dev/pdufa/debamestrocel) | BCLI |  | scheduled | "In 2026 and the upcoming years, the Company will focus on initiating and completing a Phase 3b trial and commercialization of NurOwn® for ALS, if approved." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1137883/000110465926064628/bcli-20260331xs1.htm)) |
| March 31, 2026 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "-- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465926037760/tm2610751d1_ex99-1.htm)) |
| May 15, 2026 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/tm2614771d1_ex99-1.htm)) |
| August 14, 2026 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/tm2623188d1_ex99-1.htm)) |
| November 2028 | [Debamestrocel - msc-ntf (nurown) primary completion](https://sec-api.dev/pdufa/debamestrocel-msc-ntf-nurown) | BCLI | Amyotrophic Lateral Sclerosis (ALS); Amyotrophic Lateral Sclerosis | scheduled | "NCT06973629 (Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-11-01 (ESTIMATED); Lead Sponsor Brainstorm-Cell Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973629)) |
| Nov 2028 to Feb 2029 | [Debamestrocel - msc-ntf (nurown) topline data readout](https://sec-api.dev/pdufa/debamestrocel-msc-ntf-nurown) | BCLI | Amyotrophic Lateral Sclerosis (ALS); Amyotrophic Lateral Sclerosis | scheduled | "NCT06973629 (Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-11-01 (ESTIMATED); Lead Sponsor Brainstorm-Cell Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973629)) |

## Drugs

- [NurOwn (debamestrocel)](https://sec-api.dev/pdufa/debamestrocel): mild to moderate als
- [Debamestrocel - msc-ntf (nurown)](https://sec-api.dev/pdufa/debamestrocel-msc-ntf-nurown): Amyotrophic Lateral Sclerosis (ALS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bcli/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BCLI catalysts: BRAINSTORM CELL THERAPEUTICS INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bcli/catalysts

```bibtex
@misc{secapidev_companies_bcli_catalysts_20261116,
  title        = {BCLI catalysts: BRAINSTORM CELL THERAPEUTICS INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bcli/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bcli_catalysts_20261116","title":"BCLI catalysts: BRAINSTORM CELL THERAPEUTICS INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bcli/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
